ArticleMedical oncology (Northwood, London, England)2026
Liposomal honokiol attenuates dimethylhydrazine-induced colon carcinogenesis in rats through modulation of oxidative stress, inflammation, apoptosis, autophagy, and lipid metabolism pathways.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Colorectal cancer is one of the leading causes of cancer-related mortality worldwide, and its progression is strongly associated with oxidative stress, chronic inflammation, dysregulated apoptosis, and impaired autophagy. Although honokiol (HNK) possesses promising anticancer properties, its therapeutic application is limited by poor bioavailability and low aqueous solubility. Therefore, this study investigated the potential of liposomal honokiol nanoparticles (HNK-LNPs) as an advanced nanotherapeutic strategy to enhance the chemoprotective efficacy of HNK against dimethylhydrazine (DMH)-induced colon carcinogenesis in Wistar rats. Sixty rats were randomly allocated into six groups (n = 10): normal control, HNK, HNK-LNPs, DMH, DMH + HNK, and DMH + HNK-LNPs. Experimental treatments were continued for 10 weeks. DMH administration markedly increased serum tumor markers, including AFP, CEA, CA19-9, CA125, and CA15-3, as well as vascular endothelial growth factor (VEGF) levels. DMH exposure also induced severe oxidative stress, evidenced by elevated malondialdehyde (MDA) levels and depletion of total antioxidant capacity (TAC), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx). Moreover, DMH suppressed the NRF2/HO-1 antioxidant signaling pathway and significantly increased inflammatory mediators, including NF-κB, COX-2, TNF-α, IL-6, IL-1β, and nitric oxide (NO). In addition, DMH disrupted autophagic activity through downregulation of LC3-II and Beclin-1 and activated the PI3K/AKT/mTOR/SREBP-1c signaling pathway, leading to increased expression of fatty acid synthase (FASN) and acetyl-CoA carboxylase 1 (ACC1). DMH also inhibited apoptosis, as demonstrated by reduced expression of BAX, caspase-3, and TP53, along with increased BCL-2 expression. Histopathological and ultrastructural analyses confirmed marked colonic tissue injury and cellular abnormalities in DMH-treated rats. Co-administration of HNK partially ameliorated these alterations, whereas HNK-LNPs produced substantially greater protective effects. Treatment with HNK-LNPs restored antioxidant defenses, suppressed inflammatory and lipogenic signaling pathways, enhanced autophagy and apoptosis-related markers, and markedly improved histological architecture. Overall, HNK-LNPs demonstrated superior chemoprotective efficacy compared with free HNK, suggesting that liposomal delivery enhances the therapeutic potential of honokiol against DMH-induced colon carcinogenesis.
Indexed as
Identifiers
42418059What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.